Foveal LLP Independent Investment Research Foveal Research

We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for

We present an update to our September 2020 detailed pipeline analysis “J&J NME pipeline”, examining the prospects of three new molecular ent

Last night the FDA granted accelerated approval for Merck’s Keytruda to be used in combination with pemetrexed and carboplatin chemo for...

Predictable failure of ROG anti PDL1 Tecentriq in Bladder cancer where anti PD1 succeeded: As we feared, Roche today announced that its...

AstraZeneca received accelerated FDA approval for its anti PD-L1 durvalumab (Imfinzi) in 2nd line bladder cancer last week, making this...

IDOs from Incyte are back in focus with high response rates and better safety than the existing IO combos. But will they win out...

Despite ROG last week’s Ocrevus FDA approval for PPMS & RRMS, its lack of benefit in women with PPMS and increased cancer risk and little di

Awaiting full data: Roche announced that APHINITY met its primary endpoint , but as expected details are to be published at an upcoming...

We present the third update of our APHINITY analysis, originally published two years ago and find the risks of early stage Perjeta...

Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was...